ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ:ACAD
Want to see ACAD full AI Analyst Report?
ACAD Stock Chart & Stats
$22.17
-$0.09(-0.52%)
At close: 4:00 PM EST
$22.17
-$0.09(-0.52%)
Day’s Range― - ―
52-Week Range$19.69 - $28.35
Previous CloseN/A
Volume443.16K
Average Volume (3M)1.50M
Market Cap
$3.64B
Enterprise Value$3.35B
Total Cash (Recent Filing)$851.46M
Total Debt (Recent Filing)$50.79M
Price to Earnings (P/E)9.5
Beta1.14
Next Earnings
Aug 11, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.23
Shares Outstanding171,235,870
10 Day Avg. Volume1,057,755
30 Day Avg. Volume1,503,226
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)3.69
Price to Sales (P/S)4.22
P/FCF Ratio43.02
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue3.06
Enterprise Value/Gross Profit3.35
Enterprise Value/Ebitda26.43
Forecast
1Y Price Target
$32.18Price Target Upside45.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)0.39
Revenue Forecast (FY)$1.24B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet And Cash RunwayACADIA's very low leverage and roughly $851M cash position materially strengthen financial flexibility. That runway supports commercial rollouts, near‑term readouts and R&D investment without reliance on frequent external financing, reducing refinancing risk over the next several quarters.
Profitability And Strong Gross MarginsAfter multi-year losses, ACADIA achieved sustained profitability and very high gross margins, indicating strong product economics. Durable gross margin strength means incremental revenue can fund reinvestment and absorb commercial spending, improving long‑term earnings resilience.
Commercial Momentum And Field Force ExpansionRobust DAYBUE growth, ongoing NUPLAZID demand gains and a 30% expansion of the customer‑facing sales force point to durable commercial traction. Expanded coverage and a new STIX formulation should deepen penetration and support back‑end loaded revenue growth over coming quarters.
Bears Say
Steep SG&A Increase From Commercial BuildSG&A jumped ~35% driven by salesforce growth and commercialization investments, raising the fixed cost base. If revenue acceleration underperforms expectations, operating leverage could compress margins and strain cash generation until higher sales materialize, a structural near‑term risk.
High Gross‑to‑net AdjustmentsMaterial gross‑to‑net deductions materially reduce net realizable revenue and are driven by payer rebates and discounts. These dynamics are structural for branded therapies and limit the company’s ability to convert gross sales into cash, capping sustainable free cash flow despite volume growth.
Regulatory Uncertainty For Trofinetide In EuropeAn unresolved European reexamination creates a persistent market access risk for trofinetide in a major region. An adverse decision or delayed approval would materially reduce addressable market and peak sales potential, forcing shifts in launch planning and resource allocation beyond a short‑term horizon.
ACADIA Pharmaceuticals News
ACAD FAQ
What was ACADIA Pharmaceuticals Inc.’s price range in the past 12 months?
ACADIA Pharmaceuticals Inc. lowest stock price was $19.69 and its highest was $28.35 in the past 12 months.
What is ACADIA Pharmaceuticals Inc.’s market cap?
ACADIA Pharmaceuticals Inc.’s market cap is $3.64B.
When is ACADIA Pharmaceuticals Inc.’s upcoming earnings report date?
ACADIA Pharmaceuticals Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 55 days.
How were ACADIA Pharmaceuticals Inc.’s earnings last quarter?
ACADIA Pharmaceuticals Inc. released its earnings results on May 06, 2026. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.051 by -$0.031.
Is ACADIA Pharmaceuticals Inc. overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals Inc.’s price is currently Undervalued.
Does ACADIA Pharmaceuticals Inc. pay dividends?
ACADIA Pharmaceuticals Inc. does not currently pay dividends.
What is ACADIA Pharmaceuticals Inc.’s EPS estimate?
ACADIA Pharmaceuticals Inc.’s EPS estimate is 0.06.
How many shares outstanding does ACADIA Pharmaceuticals Inc. have?
ACADIA Pharmaceuticals Inc. has 171,235,870 shares outstanding.
What happened to ACADIA Pharmaceuticals Inc.’s price movement after its last earnings report?
ACADIA Pharmaceuticals Inc. reported an EPS of $0.02 in its last earnings report, missing expectations of $0.051. Following the earnings report the stock price went up 5.028%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in ACAD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ACADIA Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.18 (45.16% Upside)
$32.18 (45.16% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 784.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.42%
12-Months-Change
Fundamentals
Return on Equity
35.65%
Trailing 12-Months
Asset Growth
41.76%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
ACAD Company Deck
ACAD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive commercial and pipeline picture: solid Q1 revenue growth (+11% adjusted), robust DAYBUE momentum (+20% YoY) and encouraging early uptake of the DAYBUE STIX formulation, continued demand and referral gains for NUPLAZID, a strong cash position ($851M) and major near‑term clinical catalysts (remlifanserin Phase II readout and trofinetide Japan Phase III). Headwinds include a temporary refill timing disruption that impacted Q1 NUPLAZID revenue timing, a sizable near‑term increase in SG&A (+35.3% YoY) to fund commercial expansion, ongoing regulatory uncertainty in Europe for trofinetide, and an R&D leadership transition. On balance, the positives (top‑line growth, product launches, reaffirmed guidance, pipeline catalysts and healthy cash) outweigh the challenges, which management describes largely as temporary or strategic investments.View all ACAD earnings summariesACAD Stock 12 Month Forecast
Average Price Target
$32.18
▲(45.16% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
PTC Therapeutics
―
Krystal Biotech
―
MoonLake Immunotherapeutics
―
―
Ownership Overview
23.27% Insiders
15.71% Mutual Funds
3.86% Other Institutional Investors
34.78% Public Companies and
Individual Investors